Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2024-01-16 Major Shareholding Noti…
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification
2024-01-16 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-26 English
SC 13D/A
Major Shareholding Notification
2023-12-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes information about a workforce reduction, cost savings initiatives, and clinical trial results, but it does not contain comprehensive financial statements or detailed financial analysis. It is not an earnings release or annual/interim report. The document is a regulatory announcement of significant corporate events rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-12-14 English
Regulatory Filings 2023
Regulatory Filings
2023-11-22 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-3. It requests the SEC to declare the registration statement effective at a specified time. The document is short (1083 characters) and does not contain financial data or report content. It is an announcement related to a regulatory filing process rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2023-11-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.